Home > > > > > Report Detail

Attention-deficit/hyperactivity disorder (ADHD) - Epidemiology Forecast to 2028

Publisher Name :
Date: 15-Jan-2019
No. of pages: 50
Delivery of the Report will take 2-3 working days once order is placed.

DelveInsight's "Attention-deficit/hyperactivity disorder (ADHD) - Epidemiology Forecast, 2028" report provides a comprehensive analysis of the Attention-deficit/hyperactivity disorder (ADHD) epidemiology, providing the historical and forecasted data for the 7MM during the forecast period from 2016-2028.

Markets Covered

- United States

- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

- Japan

Study Period: 2016-2028

Attention-deficit/hyperactivity disorder (ADHD) Epidemiology

The epidemiology section covers the historical, current as well as forecasted epidemiology for Attention-deficit/hyperactivity disorder (ADHD) in 7 major markets. The data is collected by understanding the disease, reviewing numerous studies conducted by countries and by exploring different surveys as well as reports. The Key opinion leaders' views are also taken into account to provide a deep understanding of the Attention-deficit/hyperactivity disorder (ADHD) outlook. It also includes the explanation of changing trends of epidemiology outlining the Attention-deficit/hyperactivity disorder (ADHD) scenario.

Attention-deficit/hyperactivity disorder (ADHD) Epidemiology Segmentation

The epidemiology section is further segmented according to the patient pool characteristics, such as age-specific, type-specific, sub-type specific, gender-specific etc., thus providing an in-depth and high-quality analysis. The report also covers the prevalent/Incidence cases as well as the treatable cases as per the therapies available for the Attention-deficit/hyperactivity disorder (ADHD) thereby presenting the trends with detailed analysis, with the assumptions undertaken. The data is presented in the form of graphs along with tables to effectively summarize the landscape.

Report Scope

- The report covers detailed overview of Attention-deficit/hyperactivity disorder (ADHD) explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns

- It provides the insight about the historical and forecasted patient pool for 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan

- The Attention-deficit/hyperactivity disorder (ADHD) Report assesses the disease risk and burden and highlights the unmet needs

- It also helps to recognize the growth opportunities in the 7MM with respect to the patient population

Key strengths

- 10 Year Forecast

- 7MM Coverage

- Total Cases in Attention-deficit/hyperactivity disorder (ADHD)

Key assessments

- Patient Segmentation in Attention-deficit/hyperactivity disorder (ADHD)

- Attention-deficit/hyperactivity disorder (ADHD) Risk & Burden

- Factors driving growth in a specific Attention-deficit/hyperactivity disorder (ADHD) patient population

Attention-deficit/hyperactivity disorder (ADHD) - Epidemiology Forecast to 2028

Table of Contents

1. Report Introduction
2. Attention-deficit/hyperactivity disorder (ADHD) Epidemiology Overview at a Glance
2.1. Patient Share Distribution of Attention-deficit/hyperactivity disorder (ADHD) in 2016
2.2. Patient Share Distribution of Attention-deficit/hyperactivity disorder (ADHD) in 2028
3. Disease Background and Overview: Attention-deficit/hyperactivity disorder (ADHD)
3.1. Introduction
3.2. Symptoms
3.3. Etiology
3.4. Risk Factors
3.5. Pathophysiology
3.6. Diagnosis
3.7. Treatment
4. Epidemiology and Patient Population
4.1. Key Findings
4.2. Total Prevalent/ Incident Patient Population of Attention-deficit/hyperactivity disorder (ADHD) in 7MM
4.3. Total Prevalent/ Incident Patient Population of Attention-deficit/hyperactivity disorder (ADHD) in 7MM - By Countries
5. Epidemiology of Attention-deficit/hyperactivity disorder (ADHD) by Countries
5.1. United States
5.1.1. Assumptions and Rationale
5.1.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.1.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) *
5.1.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD)*
5.1.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.2. EU5
5.3. Assumptions and Rationale
5.4. Germany
5.4.1. Assumptions and Rationale
5.4.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.4.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD)*
5.4.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD)*
5.4.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.5. France
5.5.1. Assumptions and Rationale
5.5.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.5.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD)*
5.5.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD)*
5.5.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.6. Italy
5.6.1. Assumptions and Rationale
5.6.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.6.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD)*
5.6.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD)*
5.6.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.7. Spain
5.7.1. Assumptions and Rationale
5.7.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.7.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD)*
5.7.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD)*
5.7.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.8. United Kingdom
5.8.1. Assumptions and Rationale
5.8.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.8.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD)*
5.8.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD)*
5.8.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.9. Japan
5.9.1. Assumptions and Rationale
5.9.2. Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD)
5.9.3. Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD)*
5.9.4. Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD)*
5.9.5. Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD)
6. Unmet Needs of the Attention-deficit/hyperactivity disorder (ADHD)
7. Appendix
8. Report Methodology
8.1. Sources
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
*Indication Specific

List of Tables

Table 1: Total Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in 7MM
Table 2: Total Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in 7MM by Countries
Table 3: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
Table 4: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)*
Table 5: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)*
Table 6: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
Table 7: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
Table 8: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028) *
Table 9: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028) *
Table 10: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
Table 11: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
Table 12: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028) *
Table 13: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028) *
Table 14: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
Table 15: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
Table 16: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028) *
Table 17: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028) *
Table 18: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
Table 19: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
Table 20: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028) *
Table 21: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028) *
Table 22: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
Table 23: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
Table 24: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028) *
Table 25: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028) *
Table 26: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
Table 27: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)
Table 28: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028) *
Table 29: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028) *
Table 30: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)

List of Figures

Figure 1: Total Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in 7MM
Figure 2: Total Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in 7MM by Countries
Figure 3: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
Figure 4: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)*
Figure 5: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)*
Figure 6: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in United States (2016-2028)
Figure 7: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
Figure 8: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028) *
Figure 9: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028) *
Figure 10: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Germany (2016-2028)
Figure 11: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
Figure 12: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028) *
Figure 13: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028) *
Figure 14: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in France (2016-2028)
Figure 15: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
Figure 16: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028) *
Figure 17: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028) *
Figure 18: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Italy (2016-2028)
Figure 19: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
Figure 20: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028) *
Figure 21: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028) *
Figure 22: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Spain (2016-2028)
Figure 23: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
Figure 24: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028) *
Figure 25: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028) *
Figure 26: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in UK (2016-2028)
Figure 27: Prevalent/Incident Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)
Figure 28: Sub-Type Specific cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028) *
Figure 29: Sex- Specific Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028) *
Figure 30: Diagnosed Cases of the Attention-deficit/hyperactivity disorder (ADHD) in Japan (2016-2028)

  • Global Divalproex Sodium Market Research Report 2024
    Published: 08-Jan-2024        Price: US 2900 Onwards        Pages: 81
    Divalproex Sodium is used to treat certain types of seizures (epilepsy). This medicine is an anticonvulsant that works in The brain tissue to stop seizures. Divalproex Sodium is also used to treat The manic phase of bipolar disorder (manic-depressive illness), and helps prevent migraine headaches. This medicine is available only with your doctor's prescription. The global Divalproex Sodium market was valued at US$ 2188.5 million in 2023 and is anticipated to reach US$ 33......
  • Global Divalproex Sodium Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 90
    According to our LPI (LP Information) latest study, the global Divalproex Sodium market size was valued at US$ 2140.9 million in 2023. With growing demand in downstream market, the Divalproex Sodium is forecast to a readjusted size of US$ 3312 million by 2030 with a CAGR of 6.4% during review period. The research report highlights the growth potential of the global Divalproex Sodium market. Divalproex Sodium are expected to show stable growth in the future market. However, product differ......
  • Global Quetiapine Fumarate Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 115
    According to our LPI (LP Information) latest study, the global Quetiapine Fumarate market size was valued at US$ 156.2 million in 2023. With growing demand in downstream market, the Quetiapine Fumarate is forecast to a readjusted size of US$ 132.9 million by 2030 with a CAGR of -2.3% during review period. The research report highlights the growth potential of the global Quetiapine Fumarate market. Quetiapine Fumarate are expected to show stable growth in the future market. However, produ......
  • Global Clozapine Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 114
    According to our LPI (LP Information) latest study, the global Clozapine market size was valued at US$ 341.4 million in 2023. With growing demand in downstream market, the Clozapine is forecast to a readjusted size of US$ 463.4 million by 2030 with a CAGR of 4.5% during review period. The research report highlights the growth potential of the global Clozapine market. Clozapine are expected to show stable growth in the future market. However, product differentiation, reducing costs, and s......
  • Global Trazodone Hydrochloride (API) Market Growth 2024-2030
    Published: 04-Jan-2024        Price: US 3660 Onwards        Pages: 92
    According to our LPI (LP Information) latest study, the global Trazodone Hydrochloride (API) market size was valued at US$ million in 2023. With growing demand in downstream market, the Trazodone Hydrochloride (API) is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during review period. The research report highlights the growth potential of the global Trazodone Hydrochloride (API) market. Trazodone Hydrochloride (API) are expected to show stable growth in the future......
  • Global Trazodone Hydrochloride (API) Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
    Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 93
    According to our (Global Info Research) latest study, the global Trazodone Hydrochloride (API) market size was valued at USD million in 2023 and is forecast to a readjusted size of USD million by 2030 with a CAGR of % during review period. Trazodone, a phenylpiperazine-triazolopyridine antidepressant, was originally discovered and developed in Italy in the 1970s by Angelini research laboratories. Trazodone is used to treat depression and to treat the combination of symptoms of anxiety an......
  • Global Divalproex Sodium Market 2024 by Manufacturers, Regions, Type and Application, Forecast to 2030
    Published: 01-Jan-2024        Price: US 3480 Onwards        Pages: 91
    According to our (Global Info Research) latest study, the global Divalproex Sodium market size was valued at USD 2251.9 million in 2023 and is forecast to a readjusted size of USD 3371.1 million by 2030 with a CAGR of 5.9% during review period. Divalproex Sodium is used to treat certain types of seizures (epilepsy). This medicine is an anticonvulsant that works in the brain tissue to stop seizures. Divalproex Sodium is also used to treat the manic phase of bipolar disorder (manic-d......
  • Global Risperidone Market Research Report 2023
    Published: 28-Dec-2023        Price: US 2900 Onwards        Pages: 93
    This report, based on historical analysis (2018-2022) and forecast calculation (2023-2029), aims to help readers to get a comprehensive understanding of global Risperidone market with multiple angles, which provides sufficient supports to readers' strategy and decision making. By Company - Janssen (Johnson & Johnson) - Ajanta Pharma - Amneal Pharmaceuticals - Aurobindo Pharma - Hikma - Sandoz - Lannett - Tris Pharma - Ap......
  • Global Schizophrenia Therapeutics Market Status and Outlook 2023-2028
    Published: 27-Dec-2023        Price: US 3160 Onwards        Pages: 101
    Schizophrenia is usually treated with an individually tailored combination of talking therapy and medicine. Most people with schizophrenia are treated by community mental health teams (CMHTs). The goal of the CMHT is to provide day-to-day support and treatment while ensuring you have as much independence as possible. Our market research experts provide qualitative and quantitative analysis of the market based on involving economic and non-economic factors in the same report with market va......
    • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - [email protected] / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs